GLP-1 Therapy Management for Cardiometabolic Health

Explore the effects of GLP-1 therapy on cardiometabolic health and discover potential benefits for patients.

Abstract

In this educational post, I guide you through a clear, stepwise exploration of modern incretin-based therapies—particularly GLP-1 receptor agonists and dual GIP/GLP-1 agents—and how they transform outcomes for people living with type 2 diabetes, obesity, cardiovascular disease, and chronic kidney disease. I explain the physiology of incretin signaling, the pharmacology and clinical differences among agents, and the evidence for reductions in major adverse cardiovascular events, slowing of kidney disease progression, improvements in heart failure symptoms, and weight-loss-related improvements in obstructive sleep apnea. I detail how to select and titrate medications without over-basalizing insulin, and I share practical, integrative strategies from my clinical work—spanning neuromusculoskeletal care, autonomic regulation, sleep optimization, anti-inflammatory nutrition, and structured movement—that complement pharmacology in a patient-centered model aligned with ADA, AHA/ACC, and KDIGO guidance. I also cover advanced topics, including renal outcomes (FLOW), cardiovascular risk reduction in people without diabetes (SELECT), heart failure symptom improvement (STEP HFpEF), and personalized switching strategies among GLP-1 agents, including tirzepatide. Throughout, I integrate real-world insights from my clinical practice and collaborations to help you put this into action.

The Cardiometabolic Big Picture: Why We Treat Beyond Glucose

When I meet a patient with type 2 diabetes, I see far more than a blood sugar problem. People with diabetes carry a disproportionate burden of atherosclerotic cardiovascular disease (ASCVD)—heart attacks, strokes, and peripheral arterial disease—even when A1C looks “good.” The drivers of harm extend beyond hyperglycemia to include insulin resistance, visceral adiposity, endothelial dysfunction, chronic inflammation, autonomic imbalance, and renal microvascular injury (American Diabetes Association [ADA], 2024).

Key pillars that shape my modern strategy:

• ASCVD remains the leading cause of death among people with type 2 diabetes (ADA, 2024).
• Multisystem dysfunction requires comprehensive risk reduction across blood pressure, lipids, glucose, weight, kidney protection, and lifestyle (ADA, 2024; Arnett et al., 2019; KDIGO, 2020).
• Integrating metabolic, vascular, and renal goals ensures we treat the whole cardiometabolic axis rather than chasing glucose alone.

As a chiropractor and advanced practice clinician, I focus on building systemic metabolic resilience. That means addressing the whole network—glycemia, adiposity, vascular tone, autonomic regulation, inflammatory load, and tissue mechanics—because each pillar influences the others, and change becomes most durable when these elements move together.

Understanding the Incretin Effect: The Science Behind GLP-1 and GIP

To use GLP-1 therapies effectively, we must understand the incretin effect—the observation that oral glucose produces more insulin than intravenous glucose due to gut-hormone signaling. After a meal, intestinal L-cells release glucagon-like peptide-1 (GLP-1), and K-cells release glucose-dependent insulinotropic polypeptide (GIP). These hormones act in a glucose-dependent manner, amplifying insulin when glucose is high and moderating glucagon—providing a built-in safety brake against hypoglycemia (Drucker & Nauck, 2006; Holst & Vilsbøll, 2013).

What GLP-1 and GIP do physiologically:

• GLP-1 increases glucose-dependent insulin secretion, suppresses glucagon during hyperglycemia, slows gastric emptying, and stimulates hypothalamic satiety circuits to reduce appetite (Holst & Vilsbøll, 2013).
• GLP-1 receptor activation improves endothelial function, reduces vascular inflammation, and supports natriuresis and renal hemodynamics via direct and indirect mechanisms (Verma & McMurray, 2018; Mann et al., 2020).
• GIP, once considered peripheral to weight control, appears to modulate adipose tissue dynamics; when paired with GLP-1—as in tirzepatide—we see amplified reductions in A1C and body weight (Frías et al., 2021).

Why this matters clinically:

• Postprandial hyperglycemia drives oxidative stress, endothelial injury, and macrovascular risk. GLP-1 agents blunt these excursions and reduce glycemic variability, a key contributor to vascular harm.
• Appetite modulation and delayed gastric emptying smooth daily glucose curves and reduce caloric intake—vital for weight-centered care.
• Beyond glycemia, mechanistic vascular and renal effects make these medications central to risk reduction in high-risk populations.

Avoiding Over-Basalization: Rethinking Insulin with Incretin Support

Over time, many patients end up on high-dose basal insulin while still missing A1C targets. The giveaway is near-target fasting glucose with persistent postprandial spikes—a sign we are covering hepatic glucose output with basal insulin but not addressing mealtime dysregulation (ADA, 2024). In those cases, adding more basal insulin increases the risk of weight gain and hypoglycemia without solving the real problem.

My approach:

• Keep basal insulin aligned to hepatic glucose output.
• Prioritize a GLP-1 receptor agonist to target postprandial hyperglycemia, reduce total insulin needs, and support weight loss (Buse et al., 2011).
• Use continuous glucose monitoring (CGM) or structured SMBG to verify patterns and titrate thoughtfully.

Why GLP-1 first? It restores physiologic balance, reduces total insulin exposure, and addresses weight and cardiometabolic risk in one intervention—consistent with ADA and AHA/ACC risk-focused priorities.

Case Journey 1: Naomi’s Over-Basalization and Integrated Plan

Naomi, 66, has 12 years of type 2 diabetes. A1C is 8.3%. She has hyperlipidemia, hypertension, proteinuria, and early CKD risk factors. Medications include degludec 66 units daily, metformin 1,000 mg BID, a statin, an ARB, and an SGLT2 inhibitor. Fasting glucose: 140–160 mg/dL; bedtime: 160–170 mg/dL. BMI is 32.5.

What her data tells me:

• Basal insulin is substantial, yet A1C remains elevated—suggesting postprandial dysregulation.
• Proteinuria and cardiometabolic risk call for therapies with cardiovascular and renal benefits.
• Weight remains a modifiable driver of insulin resistance, blood pressure, and lipid imbalance.

My plan:

• Initiate a GLP-1 receptor agonist ahead of prandial insulin to improve post-meal control and aid weight loss directly.
• Consider semaglutide or dulaglutide for established MACE reduction, and monitor renal markers; discuss tirzepatide if weight-loss goals are paramount.
• Reduce basal insulin by 10–20% at initiation if hypoglycemia risk emerges with appetite changes; fine-tune based on fasting profiles and CGM.

Lifestyle and integrative care:

• Protein-centered meals (20–30 g per meal), fiber-rich vegetables, modest healthy fats, and low-glycemic carbohydrates timed earlier in the day to match circadian insulin sensitivity.
• Post-meal movement: 10–15 minutes of walking or gentle resistance sets to blunt glucose excursions.
• Chiropractic integration: manual therapies to reduce pain load and optimize rib-cage and pelvic mechanics, enabling daily activity; breathing drills to enhance vagal tone and sleep quality.
• Sleep hygiene: fixed sleep window, evening light control, nasal breathing, and positional strategies to reduce OSA burden as weight declines.

Monitoring and contingencies:

• CGM targets with a coefficient of variation under 36%.
• Reassess A1C at 12 weeks; track weight, waist, BP, and urinary albumin-to-creatinine ratio.
• If post-meal spikes persist at the target GLP-1 dose, add low-dose prandial insulin at the largest meal while maintaining weight-loss and integrative supports.

Comparing GLP-1 and Dual Incretin Agents: Efficacy, Safety, and Selection

We now have several potent options, each with unique strengths:

• Semaglutide (Ozempic/Wegovy): Substantial A1C lowering (~1–1.5%), significant weight loss, and established MACE reduction; robust obesity data and benefits in select non-diabetes populations (Marso et al., 2016; Wilding et al., 2021).
• Dulaglutide (Trulicity): Strong A1C reduction (~1%) with documented MACE reduction in a broad risk cohort (REWIND) (Gerstein et al., 2019).
• Liraglutide (Victoza/Saxenda): Daily dosing; proven MACE reduction (LEADER) with good weight and glycemic effects (Marso et al., 2016).
• Exenatide (Byetta/Bydureon): Earlier agent with moderate efficacy; less preferred where cardiometabolic endpoints are prioritized (Drucker & Nauck, 2006).
• Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 agonist delivering powerful A1C and weight loss outcomes—often exceeding semaglutide; carries an indication for obesity and OSA via weight-loss mechanisms; cardiovascular outcomes are evolving and promising (Frías et al., 2021; Jastreboff et al., 2022).

How I choose:

• If ASCVD risk reduction and renal signals are top priorities with strong weight loss, start with semaglutide or dulaglutide due to established CVOTs; consider tirzepatide when maximal weight loss is needed, and contraindications are absent.
• If daily routine favors adherence and an established CV benefit is desired, liraglutide is a solid choice.

Titration, Tolerability, and Co-Therapies: Protocols That Work

GLP-1 agents are highly effective, and success hinges on thoughtful titration and lifestyle alignment.

My titration principles:

• Start low and go slow. For semaglutide, begin at 0.25 mg weekly, then 0.5 mg and 1.0 mg at 4-week intervals as tolerated; escalate further for obesity treatment as indicated.
• Encourage small, protein-forward meals, limit highly processed carbohydrates, and avoid large, high-fat meals during titration to reduce nausea.
• Maintain hydration and consider ginger or peppermint if nausea arises; adjust timing or temporarily step back a dose if needed.

Co-therapy considerations:

• When adding GLP-1 to substantial basal insulin, reduce the basal dose by 10–20% if hypoglycemia risk is present, then titrate based on fasting profiles.
• Continue metformin unless contraindicated; preserve SGLT2 inhibitors for kidney and heart benefits, with attention to hydration status and the risk of rare euglycemic ketoacidosis in very low-carb contexts.
• Avoid DPP-4 inhibitors when on GLP-1 therapy due to redundant mechanisms and lack of added benefit.

Safety essentials:

• Contraindications include personal/family history of medullary thyroid carcinoma or MEN2; exercise caution with prior pancreatitis and monitor for gallbladder events.
• Educate patients about transient GI effects and reinforce that early satiety is part of how the medication works (Mann et al., 2020; ADA, 2024).

Evidence-Based Outcomes: Cardiovascular, Renal, Weight, and OSA

Why guidelines prioritize these agents:

• Cardiovascular outcomes: Liraglutide, dulaglutide, and semaglutide have shown significant reductions in MACE in high-risk populations (Marso et al., 2016; Gerstein et al., 2019).
• Renal protection: GLP-1 agents reduce albuminuria and may slow eGFR decline; the FLOW trial (stopped early for benefit) supports the role of semaglutide in slowing CKD progression (Mann et al., 2020; FLOW Trial Results for Semaglutide, 2024).
• Weight loss: Clinically meaningful reductions improve insulin sensitivity, blood pressure, and lipids; tirzepatide often produces the largest average reductions to date (Wilding et al., 2021; Jastreboff et al., 2022; Frías et al., 2021).
• OSA: Weight reduction improves OSA severity; tirzepatide holds an FDA indication for OSA tied to weight loss.

Mechanistic underpinnings:

• Lower postprandial glucose variability reduces oxidative stress and endothelial injury.
• Central satiety pathways (POMC/CART and melanocortin signaling) curb hyperphagia and late-night snacking.
• Direct vascular effects may include improved nitric oxide bioavailability and dampened NF-κB inflammatory signaling (Verma & McMurray, 2018).

Advanced Evidence Update: SELECT, STEP HFpEF, and ADA 2025 Positioning

We have entered a new era in which incretin therapies address risk far beyond glucose:

• SELECT (2023): In overweight or obese adults with established CVD but no diabetes, semaglutide 2.4 mg reduced MACE by ~20% over 33 months—proof of cardioprotection independent of glycemic change (SELECT Trial: Semaglutide in CVD without Diabetes, 2023).
• STEP HFpEF (2023): In patients with obesity and HFpEF, semaglutide 2.4 mg improved heart failure-related symptoms and functional limitations while inducing substantial weight loss (STEP HFpEF: Semaglutide in Obesity and HFpEF, 2023).
• ADA 2025 Standards: Prioritize GLP-1 receptor agonists and SGLT2 inhibitors for patients with ASCVD, heart failure, or CKD; note semaglutide’s renal indication and emphasize risk-oriented therapy selection even before metformin in select high-risk cases (Standards of Medical Care in Diabetes—2025, 2025).

Clinical implications:

• GLP-1 therapies are now core cardio-renal-metabolic. In many high-risk patients, they belong at the front of the line alongside SGLT2 inhibitors.

---

Balancing Body and Metabolism- Video

---

Beyond Metabolism: Neuroprotective Signals, Craving Reduction, and Women’s Health

I frequently discuss emerging and off-label areas with patients, emphasizing that these are developing fields requiring shared decision-making.

Neuroprotective signals:

• Early trials and observational data suggest potential benefits in Parkinson’s disease and cognitive decline via central GLP-1 receptor engagement, reduced neuroinflammation, and improved mitochondrial function (Athauda & Foltynie, 2016; GLP-1 and CV Mechanisms, 2021).
• Some reports describe seizure reduction; while mechanistic plausibility exists, this remains an area of exploration.

Cravings and reward:

• Many patients report fewer cravings for food, nicotine, or alcohol—likely via modulation of mesolimbic dopamine (reward valuation) and stabilized energy states. I leverage this window to build durable nutrition and movement routines and collaborate with behavioral health when needed.

Women’s health and fertility:

• In PCOS, weight loss and insulin sensitization can restore ovulation and improve fertility markers. Unexpected pregnancies (“Ozempic babies”) highlight the need for proactive contraception counseling. GLP-1 agents are not used during pregnancy, so planning is essential (Jensterle et al., 2022; American College of Obstetricians and Gynecologists, 2023).

Respiratory insights:

• Signals suggest reduced exacerbations in asthma and COPD among GLP-1 users, potentially via systemic anti-inflammatory effects and weight loss; these therapies complement, but do not replace, pulmonary standards of care (Usmani et al., 2024).

Autoimmunity contexts:

• In LADA and selected type 1 diabetes scenarios, GLP-1 agents are being studied as adjuncts for weight and metabolic control and possible beta-cell preservation. This is off-label and requires careful management of insulin and hypoglycemia with multidisciplinary oversight (Buzzetti et al., 2020; Battelino et al., 2023).

Personalized Switching Strategies: From Dulaglutide to Semaglutide or Tirzepatide

Patients often ask about switching when satiety fades or weight loss plateaus. My switching roadmap:

• Dulaglutide to semaglutide: Pause for one week, initiate semaglutide at a low dose (e.g., 0.25–0.5 mg weekly), and titrate in 4-week intervals to optimize satiety and minimize GI effects.
• Dulaglutide to tirzepatide: One-week washout, then start tirzepatide at 5 mg weekly, titrating stepwise (7.5, 10, 12.5, 15 mg) to the dose that delivers consistent satiety and ongoing weight reduction with acceptable tolerability.

Physiologic rationale:

• Each agent has unique kinetics in gastric emptying, central satiety signaling, and incretin receptor engagement. Slow titration respects the gut-brain axis, reduces GI burden, and aligns with real-world adherence (Frías et al., 2021).

I stop titration at the dose at which patients experience steady early satiety, diminished cravings, sustainable weight change, and minimal GI symptoms. This functional endpoint is more meaningful than a maximum dose for its own sake.

Integrative Chiropractic Care: How Mechanics and Autonomics Amplify Incretin Therapies

Patients ask how chiropractic care fits with incretin pharmacology. In my practice, the synergy is powerful:

• Autonomic regulation via manual therapies: Gentle spinal and rib-cage mobilization and soft-tissue work can reduce sympathetic overdrive and enhance vagal tone. Improved parasympathetic balance supports gastric motility, satiety signaling, and glycemic stability—often easing GLP-1–related GI symptoms during titration.
• Pain reduction to unlock movement: By decreasing nociception and improving load distribution through pelvic, hip, and thoracic mechanics, patients increase daily non-exercise activity thermogenesis (NEAT) and adhere to exercise prescriptions—both crucial for insulin sensitivity and weight maintenance.
• Breathing and rib mechanics: Diaphragmatic and nasal breathing improve oxygenation, reduce nocturnal sympathetic surges, and enhance sleep quality—indirectly smoothing glycemic variability and appetite.
• Neuromuscular re-education: Low-load motor control drills and progressive resistance training preserve lean mass, counter adaptive thermogenesis, and improve GLUT4-mediated glucose disposal—multiplying the metabolic gains of GLP-1 agents.
• Sleep and circadian stability: Routine sleep windows, morning light exposure, and meal timing reduce late-evening cortisol and improve fasting glucose.
• Functional nutrition: Protein-forward, fiber-rich patterns with adequate micronutrient intake pair well with GLP-1–induced satiety, minimizing GI discomfort and sustaining weight loss.

From my clinical observations and ongoing work at PushAsRx and in professional collaborations, patients who layer mechanics, autonomics, and behavior onto GLP-1 therapy achieve steadier satiety, fewer GI adverse events, improved energy, more durable weight loss, and smoother CGM curves (PushAsRx clinical insights; LinkedIn professional overview).

Case Journey 2: Tammy’s Plateau, Shared Decisions, and Personalized Progress

Tammy, 58, with a 10-year history of type 2 diabetes, had an A1C of 8.1% and a BMI above 38. She was on maximum metformin, dulaglutide 1.5 mg weekly, and dapagliflozin daily. She reported no major side effects but felt less full after meals, and her weight loss plateaued at 5 pounds.

My approach:

• Reassess pharmacotherapy: Consider transitioning from dulaglutide to semaglutide with stepwise titration to achieve greater weight and A1C benefits. If targets remain unmet or higher weight loss is needed, evaluate candidacy for tirzepatide.
• Reinforce nutrition: Aim for 30–40 g protein per meal, add viscous fibers (e.g., psyllium) for satiety and glycemic smoothing, and avoid high-fat/high-glycemic combinations.
• Integrate chiropractic and movement: Baseline postural and gait assessment; thoracic and pelvic mobility work; diaphragmatic breathing; progressive resistance training 2–3 days per week; and low-impact aerobic activity on most days.
• Monitor safety: Track triglyceride levels to assess pancreatitis risk, support hydration, titrate slowly to minimize GI symptoms, and plan pre-procedural medication holds.

If Tammy remained above glycemic targets after GLP-1 optimization, I would consider basal insulin; however, I often prioritize optimizing a dual incretin pathway or the GLP-1 dose before introducing insulin to safeguard against weight gain and hypoglycemia.

Organ Systems and Mechanisms: Why These Therapies Deliver Durable Benefits

The systemic reach of GLP-1 biology underpins broad clinical benefits:

• Brain: Enhanced satiety and potential neuroprotective effects may reduce cravings and improve adherence.
• Pancreas: Increased glucose-dependent insulin secretion and reduced glucagon attenuate hepatic glucose output.
• Gut: Slowed gastric emptying smooths postprandial spikes and fosters early satiety; GI side effects usually diminish with careful titration.
• Liver: Improved insulin signaling and weight loss reduce de novo lipogenesis and hepatic steatosis, with promise in MASH/NASH (Newsome et al., 2021).
• Vasculature: Improved endothelial function and anti-inflammatory signaling enhance nitric oxide bioavailability and plaque stability (Verma & McMurray, 2018).
• Kidney: Hemodynamic improvements and metabolic changes complement SGLT2 benefits; semaglutide’s FLOW data support renal protection (FLOW Trial Results for Semaglutide, 2024).
• Muscle and bone: Weight loss mandates the protection of lean mass and bone mineral density through resistance training, adequate protein intake, and periodic DEXA in at-risk patients (Body Composition Changes with GLP-1 Therapy, 2021).

This is why I combine pharmacology with chiropractic-informed movement, autonomic balance, and sleep: the physiology aligns, and the outcomes last.

Practical Protocols: Initiation, Monitoring, Preprocedural Holds, and Safety

Initiation and titration:

• Remain at each dose for at least 4 weeks before escalation; back down if GI symptoms persist.
• Align nutrition with GLP-1 effects by using smaller portions, protein-forward meals, and fiber timing to improve satiety and minimize nausea.

Monitoring:

• A1C every 3 months initially; CGM or structured SMBG for pattern recognition.
• Renal function, electrolytes, and lipids at baseline and periodically; urinary albumin-to-creatinine ratio for CKD risk.
• Consider DEXA for bone health during significant, sustained weight loss.
• Screen for gallbladder symptoms with rapid weight change and for mood shifts during therapy.

Preprocedural considerations:

• Due to delayed gastric emptying, hold weekly GLP-1 agents 1–2 weeks prior to procedures requiring sedation or anesthesia; coordinate with anesthesia teams (ASA consensus guidance, 2023).

Key safety points:

• Boxed warning for medullary thyroid carcinoma and MEN2—absolute contraindications.
• Watch for pancreatitis symptoms and manage hydration to prevent AKI when GI illness occurs.
• In retinopathy-prone patients, rapid glycemic improvements warrant ophthalmologic coordination.

Building a Patient-Centered Algorithm: From Risk Stratification to Adaptation

A streamlined, risk-based pathway I use in the clinic:

• Assess risks and goals:

• • ASCVD risk, CKD markers, weight targets, OSA symptoms, and functional capacity.
  • Identify over-basalization and polypharmacy opportunities.

• Choose the incretin approach:

• • GLP-1 (semaglutide/dulaglutide/liraglutide) for established cardiovascular benefit.
  • Consider tirzepatide for maximal weight loss and OSA benefits when appropriate.

• Titrate thoughtfully:

• • Start low, go slow; align meals and movement to minimize GI effects.

• Integrate chiropractic and lifestyle:

• • Reduce pain, optimize posture and gait, and prescribe post-meal walking, resistance training, sleep hygiene, and autonomic-balancing breathwork.

• Monitor and adapt:

• • Track CGM metrics, renal markers, lipids, BP, and A1C at 12-week intervals; refine basal insulin and consider prandial insulin only after optimizing incretin therapy.

Why Integration Wins: Pharmacology Meets Mechanics and Behavior

Durable outcomes arise when incretin science intersects with mechanical optimization and behavioral scaffolding:

• Pharmacology provides the biochemical shift—reduced appetite, improved insulin dynamics, and lower postprandial spikes.
• Chiropractic and functional medicine increase the body’s capacity to move, sleep, and recover—magnifying and stabilizing metabolic gains.
• Behavior change anchors new habits, making weight loss and glycemic control stick.

From PushAsRx clinical work and interdisciplinary collaborations, I consistently observe that patients who resolve pain, improve mobility, and regulate autonomic tone take more steps, sleep better, and manage cravings more easily—translating into smoother CGM traces, lower medication burdens, and higher quality of life over time.

References

• American College of Obstetricians and Gynecologists. (2023). Obesity in pregnancy: Clinical updates and guidance.
• American Diabetes Association. (2024). Standards of Medical Care in Diabetes—2024. Diabetes Care.
• Battelino, T., Danne, T., & Battelino, S. (2023). Adjunct therapies in LADA and type 1 diabetes: The role of GLP-1. Diabetologia.
• Body Composition Changes with GLP-1 Therapy. (2021). JAMA.
• Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018). Vagus nerve as modulator of the brain–gut axis. Frontiers in Psychiatry.
• Buse, J. B., et al. (2011). Exenatide added to basal insulin in type 2 diabetes. Diabetes Care.
• Buzzetti, R., Zampetti, S., & Maddaloni, E. (2020). Adult-onset autoimmune diabetes: Current knowledge and implications. Nature Reviews Endocrinology.
• Drucker, D. J., & Nauck, M. A. (2006). The incretin system: GLP-1 and GIP physiology and pharmacology. NEJM.
• FLOW Trial Results for Semaglutide. (2024). NEJM.
• Frías, J. P., et al. (2021). Tirzepatide vs. semaglutide in SURPASS-2. NEJM.
• Gerstein, H. C., et al. (2019). Dulaglutide and CV outcomes in REWIND. The Lancet.
• GLP-1 Mechanisms in Cardiovascular Disease. (2021). European Heart Journal.
• Holst, J. J., & Vilsbøll, T. (2013). Mechanisms of GLP-1 action. Diabetes Care.
• Jensterle, M., et al. (2022). GLP-1 receptor agonists in PCOS. Frontiers in Endocrinology.
• Jastreboff, A. M., et al. (2022). Tirzepatide for obesity in SURMOUNT-1. NEJM.
• (2020). Clinical Practice Guideline for Diabetes Management in CKD.
• LEADER: Liraglutide and Cardiovascular Outcomes. (2016). NEJM.
• Newsome, P. N., et al. (2021). Semaglutide in NASH. NEJM.
• PIONEER Program: Oral Semaglutide. (2019–2020). The Lancet.
• SELECT Trial: Semaglutide in CVD without Diabetes. (2023). NEJM.
• Standards of Medical Care in Diabetes—2025. (2025). ADA.
• STEP HFpEF: Semaglutide in Obesity and HFpEF. (2023). NEJM.
• SUSTAIN-6: Semaglutide CV Outcomes. (2016). NEJM.
• Usmani, O. S., Singh, D., & Martinez, F. J. (2024). GLP-1 therapies and respiratory outcomes. Thorax.
• Verma, S., & McMurray, J. J. V. (2018). GLP-1 RAs and heart failure: Mechanisms and implications. Circulation.
• Wilding, J. P. H., et al. (2021). STEP-1: Once-weekly semaglutide in overweight/obesity. NEJM.

Additional clinical insights:

• Practice observations and integrative frameworks: https://pushasrx.com/
• Professional overview and methods: https://www.linkedin.com/in/dralexjimenez/

SEO tags: GLP-1, GIP, tirzepatide, semaglutide, dulaglutide, liraglutide, incretin therapies, type 2 diabetes, cardiovascular risk, CKD, kidney protection, obesity, OSA, HFpEF, SELECT trial, FLOW trial, REWIND, LEADER, SUSTAIN-6, PIONEER, postprandial glucose, over-basalization, CGM, endothelial function, nitric oxide, NF-kB, autonomic balance, chiropractic integration, vagal tone, rib-cage mechanics, diaphragmatic breathing, resistance training, protein-forward nutrition, ADA 2025, AHA/ACC, KDIGO, weight loss, MACE reduction, renal outcomes